Kornimate/medical-research-clean huggingface dataset:
genomic changes in childhood acute lymphoblastic leukemia

Conditions: Acute Lymphoblastic Leukemia

Summary: to study the genomics with cell cycle and lymphocyte differentiation in disease, remission and relapse of childhood acute lymphoblastic leukemia. then correlate these data with age, white cell count, cytogenetic changes, response to the chemotherapy and prognosis.

in order to know the genomic evolution of childhood acute lymphoblastic leukemia, we will collect bone marrow (10c.c.) at diagnosis, remission and relapse. we will do the following genes in addition to gene-chip including ikzf1,etv6, ebf1, nr3c1, rag1/g2, tcf3, btla, pax5,lef1, erg and vpreb1.we will study the gene dosages and degree of methylation. the estimated patients numbers will be 300-400. then we will correlate these data with patients'age, white blood cell count at diagnosis, cytogenetic abnormalities, response to the chemotherapy and prognosis.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed as acute lymphoblastic leukemia 2. age less than or equal to 18 years old 3. signed informed consent exclusion criteria: 1. who is not acute lymphoblastic leukemia 2. who did not sign informed consent

Keywords: genomic childhood acute lymphoblastic leukemia
non-contact dcs-speckle multi-parameter imaging for neurological diseases

Conditions: Brain Injuries; Brain Edema; Optical Imaging

Summary: this study aims to evaluate brain injuries and brain edema with non-contact dcs-speckle multi-parameter imager.

brain injuries includes acute and chronic injuries located in cerebral hemispheres, cerebellum, and brain stem, while brain edema is increased intracellular or extracellular fluid in brain tissue. early diagnosis is helpful to improve the cure rate and reduce sequelae. this study aims to evaluate brain injuries and brain edema with non-contact dcs-speckle multi-parameter imager, so as to provide reference diagnostic criteria by image artificial intelligence analysis.

Eligibility criteria:
inclusion criteria: * patients who have had brain damage. * patients who have had brain edema. * healthy people who are interested in non-contact dcs-speckle multi-parameter imaging exclusion criteria: * patients who are in pregnancy or have plan to conception. * patients who have vertebra surgery or have plan to surgery. * patients who are inappropriate to join this trial judged by the radiologists or specialists. * aids, active hepatitis, tuberculosis, syphilis * patients who regularly take anticoagulants, antiplatelet drugs

Keywords: dcs-speckle brain injuries brain edema
weekly versus no routine ventilator circuit changes in nicu

Conditions: Pneumonia, Ventilator-Associated

Summary: the purpose of this study is to determine incidence of ventilator-associated pneumonia compared between weekly and no routine ventilator circuit changes in neonatal intensive care unit

parents were received informed consent. enrolled neonates was randomly assigned to 2 groups as 7-day ventilator circuit change and no change group by computerization with allocated of concealment. the investigation team opened the next sequentially numbered study pack, which was stored in the neonatal unit. the assignment sequence was generated with balance within random block sizes of 4. stratification according to birthweight was done before randomization to control for differences in patient populations. patient characteristics were recorded as gestational age, sex, birthweight, underlying disease, date of intubation, date of extubation, duration of mechanical ventilator, reintubation, length of hospital stay, parenteral nutrition, medication (h2-blocker, ppi, narcotic drugs), transfusion and oral immune therapy. laboratory data and radiographic data were recorded. both groups received similarly care as the nurse was assigned to take care of patient in ratio 1-2 patients: 1 nurse, new disposable circuits were use in both groups and the vap prevention protocol and the endotracheal suctioning protocol which followed by an american academy of respiratory care (aarc) clinical practice guidelines were performed in both groups. when the vap was suspected the radiographic data were reviewed by two pediatric radiologists on the day of diagnosis, 3 days prior to the diagnosis and/or 2 and 7 days after diagnosis to confirm diagnosis of vap if there is different in the results, the consensus must be made.

Eligibility criteria:
inclusion criteria: * all neonates who admitted at neonatal intensive care unit (nicu) and required ventilator support with both intubated at time of neonatal resuscitation and within the nicu as indicated exclusion criteria: * patient was extubated or died within 2 calendar days of endotracheal intubation * pneumonia was diagnosed before intubation * outborn who was intubated before referred * parents declined to participate * incompatibility of disposable circuits and ventilator * chromosome abnormality or moribund

Keywords: infant, newborn neonatal intensive care unit ventilator circuit
alpha-stim aid and major depressive disorder

Conditions: Depressive Disorder, Major

Summary: the study will be a multi-centre parallel group, double blind, non-commercial, randomised controlled superiority trial. study participants will be referred from primary care gp practices via their gp and randomised into active alpha-stim aid cranial electrotherapy stimulations (ces) or sham alpha-stim aid ces.


Eligibility criteria:
inclusion criteria: * aged 16 years and above. there is no maximum age limit. * diagnosis of current major depressive episode (mde). this will be confirmed using the research version of the structured clinical interview for dsm-5 (scid-5-rv) at baseline. * a score of ≥10 to 19 on 9-item self-rated personal health questionnaire (phq-9). * have either been offered the option of antidepressant medication or have been prescribed antidepressant medication for a minimum of 6 weeks in the last 3 months. * capable of giving oral and written informed consent to the study. * agrees to return alpha-stim equipment at the end of the study and not to purchase this equipment privately during the study. exclusion criteria: * a score of ≥20 on the phq-9. * neurological conditions e.g. brain neoplasm, cerebrovascular events, epilepsy, neurodegenerative disorders, and prior brain surgery * requires urgent clinical care such as having persistent suicidal ideation, self-harm or suicidal intent. * known to be pregnant. * implantation with a pace maker, cochlear implant or an implantable cardioverter device (icd). * major unstable medical illness requiring further investigation or treatment. * a diagnosis of current substance use disorder or dependence, dementia, eating disorder, bipolar disorder or non-affective psychosis because the use of ces treatment would otherwise require additional supervision or is associated with additional risk e.g. of mania in bipolar disorder. determination of these conditions will be confirmed using a diagnostic clinical interview (scid-5-rv). * completed and benefitted from/responded to psychological treatment for depression in the last 3 months or planning to commence psychological treatment in the next 6 months. * involved with any other clinical trial at the time of consent or 6 months prior.

Keywords: depression alpha-stim cranial electrotherapy stimulation (ces)
influence of keratoconus on stress at work

Conditions: Keratoconus in One or Two Eyes for Case; Good Visual Acuity for Control

Summary: keratoconus is a progressive disorder in which central and paracentral corneal stromal thinning occurs. no studies evaluated the influence of keratoconus on stress at work, nor the influence of treatments of keratoconus on stress at work, including quality of life at work and on perception of work. moreover, it has been shown that some pathologies had greater influence in some occupations, also depending on other characteristics of individuals such as age, sex or socio professional groups. therefore, we hypothesized that keratoconus 1) will influence stress at work including qol at work and perception of work, 2) will have a greater influence in some occupations and depending on age, sex, or stage of keratoconus, 3) will induce stoppage of work and occupational reclassifications.

this is a descriptive, prospective, observational, monocentral study. for each patient with keratoconus and patient control, use of the auto questionnaire to carry out the study. we only assessed data from usual routine practice. stress at work is measured by job content questionnaire of karasek issued during consultations. study all workers the influence of keratoconus and its stage on: * consequences of keratoconus in function of visual acuity, mode of correction and staging of the keratoconus. * psychological consequences: quality of life at work, perception of work (karasek questionnaire), anxiety and depression (had scale) * professional consequences: stoppage of work and duration and occupational reclassifications * characteristics of the patient: age, sex, occupation. measures to reduce or avoid bias: * standardized, anonymous auto questionnaire * a large workforce: high rate of participation is expected * inclusion of control group.

Eligibility criteria:
inclusion criteria: * patients with keratoconus all stages followed at the chu gabriel montpied, * patients constituting a representative control group of workers consulting in ophthalmology service of clermont-ferrand. exclusion criteria: * an other ophtalmological disease alters visual acuity. * minors subjects * inability to provide informed consent

Keywords: keratoconus karasek stress at work
validation of kujala german

Conditions: Validation of Kujala Score German Version in Patients With Patellofemoral Instability and Scheduled MPFL-reconstruction

Summary: the field of patellofemoral disorders and accordant therapeutical interventions is a high turnover research field. it is important to verify the clinical outcome with appropriate measuring tools. there is evidence that the kujala score is a reliable and widely used measuring instrument of patellofemoral disorders. indeed, the kujala score was already used in many studies investigating patellofemoral disorders - also in german speaking patient groups. unfortunately, we are not aware of a validated german version of the kujala score. other relevant knee outcome scores were already successfully translated into german language and validated by previous investigators. so, it is the aim of our study to cross-culturally adapt and then to validate the kujala score for use in german-speaking individuals with patellofemoral instability. it is hypothesized that the german version of the kujala score shows: * high divergent construct validity as determined by significant differences between patients and controls (hypothesis 1) * high convergent construct validity as determined by significant correlations with other relevant scoring systems (hypothesis 2) * high reliability (hypothesis 3) * high responsiveness (hypothesis 4)


Eligibility criteria:
inclusion criteria: * german speaking * mpfl-reconstruction planed exclusion criteria:
adjuvant melatonin for prevention of lung cancer recurrence and mortality

Conditions: Non Small Cell Lung Cancer

Summary: there is evidence to support the use of melatonin, a natural health product, as an additional treatment aid for cancer patients. this study is designed to see if the daily ingestion of 20 milligrams of melatonin for one year can lower the incidence of developing lung cancer recurrence and/or death. only patients with a diagnosis of non small cell lung cancer who are eligible for surgical resection can participate in the trial. the study will also be assessing for changes in quality of life, pain, fatigue, anxiety, sleep, and depression amongst the participants.

the trial employs a two-armed parallel placebo controlled trial design whereby patients with a diagnosis of non small cell lung cancer are randomized to receive either 20 mg of melatonin nightly or an identically matched placebo. all patients will be followed for two years with primary outcomes assessed at a two year time point and secondary outcomes evaluated throughout the course of the trial.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of non small cell lung cancer * eligible for surgical resection * willingness to adhere to randomized treatment * availability for follow-up schedule of visits exclusion criteria: * taking exogenous melatonin

Keywords: melatonin natural health product (nhp) lung cancer complementary and alternative medicine (cam) randomized clinical trial
thiamine as a metabolic resuscitator after cardiac arrest

Conditions: Cardiac Arrest

Summary: this is a randomized, double-blind, placebo controlled study to investigate the effect of intravenous thiamine (vitamin b1) on lactate, cellular oxygen consumption, global oxygen consumption and biomarkers of neurologic injury after out-of-hospital cardiac arrest (ohca). .

this is a randomized, double-blind, placebo controlled study to investigate the effect of intravenous thiamine (vitamin b1) on lactate, cellular oxygen consumption, global oxygen consumption and biomarkers of neurologic injury after out-of-hospital cardiac arrest (ohca). patients who have sustained return of spontaneous circulation (rosc) after ohca and have a lactate of 3 or greater will be eligible for the study. enrolled patients will be randomized to intravenous thiamine 500mg twice daily for 5 doses or matching placebo (100cc normal saline). blood will be drawn at several time points and patients will be connected to a noninvasive monitor for continuous measurement of global oxygen consumption. the primary endpoint is change in lactate level. secondary endpoints include change in pyruvate dehydrogenase activity, change in cellular and global oxygen consumption, change in nse and s100 (biomarkers of neurologic injury) and cpc-e score (a score that assesses neurologic and functional impairment) at hospital discharge, 30 and 90 days.

Eligibility criteria:
inclusion criteria: * adult patient (age ≥ 18 years) * cardiac arrest occurring with sustained (\> 20 minutes) return of spontaneous circulation (rosc) * within 4.5 hours of cardiac arrest event * lactate \>/=3 exclusion criteria: * clinical indication for thiamine administration (alcoholism, known or highly suspected deficiency) or treatment with thiamine beyond the amount found in a standard multivitamin within the last 10 days * traumatic etiology of arrest * comfort measures only or anticipated withdrawal of support within 24 hours * protected populations (pregnant women, prisoners) * known allergy to thiamine

Keywords: cardiac arrest post-arrest
lifestyles, arterial aging and intestinal microbiota (mivas iii study)

Conditions: Arterial Stiffness; Dysbiosis

Summary: this is an observational cross-sectional study whose objective is to analyse associations between the intestinal and salivate microbiota with lifestyles (eating patterns, physical activity, tobacco and alcohol consumption), arterial aging and cognitive function. it will take place in five different research units located in spain

aim: to analyze the association of lifestyles (eating patterns, physical activity, tobacco and alcohol consumption) with the intestinal and salivate microbiota and its relationship with arterial aging and cognitive function in subjects without cardiovascular disease in spain and portugal. in addition, the mediating role of the intestinal microbiota in the relationship of lifestyles with arterial aging and cognitive function will be analyzed. design: a cross-sectional study with a case-control analysis, to analyze the association of microbiota patterns with arterial ageing. setting: the study will develop the research network in health prevention and promotion (rediapp) and in the iberian network on arterial structure and the cancer research center of salamanca. study population: 1000 subjects aged 45 to 74 years without cardiovascular disease, will be selected. variables: demographic, anthropometric and habits (tobacco and alcohol). a dietary pattern through a frequency consumption questionnaire (ffq), the software of the evident iii and the mediterranean diet adherence questionnaire. physical activity: international physical activity questionnaire (ipaq), marshall questionnaire and accelerometer, actigraph. body composition (inbody 230 impedance meter). arterial aging: medium intimate carotid thickness (sonosite micromax); analysis (pwa) and pulse wave velocity (cf-pwv), (sphygmocor system). cardio ankle vascular index (cavi), ba-pwv and ankle-brachial index (vasera vs-2000®). with ambulatory pulse wave analysis (microsoft®), the paix and caix and the heart rate variability will be measured. the vascular damage in the retina, heart, kidney, brain and cardiovascular risk will be measured. intestinal microbiota with the omnigene gut kit (omr -200) and analysis of the 16s rrna microbiome profile by massive sequentiation. (lifestyles, arterial aging, neurocognition, microbiota)

Eligibility criteria:
inclusion criteria: * people aged 45 to74 years who agree to participate in the study and who not meet any of the exclusion criteria exclusion criteria: * participants with a personal history of cardiovascular disease (ischaemic heart disease or stroke, peripheral arterial disease or heart failure) * participants with a bmi\> 40 kg / m2 * participants diagnosed renal failure in terminal stages (gfr \<30 ml / min); * chronic intestinal inflammatory disease or acute inflammatory process in the past 3 months * oncology disease diagnosed in the last 5 years or with active treatment * participants who are in a terminal condition * consumption of antibiotics last 15 days

Keywords: lifestyles pulse wave velocity intestinal microbiota multicentric study
immunomodulatory therapy & vsa

Conditions: Vasospastic Angina

Summary: vasospastic angina (vsa) is caused by brief spasms of the main coronary artery and its major branches, resulting in varying degrees of luminal occlusion. although vasodilator therapy is widely used and significantly alleviates vsa symptoms, it has not led to notable improvements in the prognosis of patients with vsa. recent studies have suggested that inflammation plays a crucial role in vsa. this study aimed to evaluate the potential effectiveness of immunomodulatory therapy for improving patient prognosis.


Eligibility criteria:
inclusion criteria: (1) transient total or subtotal occlusion of the coronary artery (contraction \>90%) observed either spontaneously or in response to irritant stimulation (typically acetylcholine, ergot, or hyperventilation); (2) presence or absence of ischemic electrocardiogram changes during episodes; (3) nitrate-responsive angina during spontaneous episode: rest angina and/or marked diurnal variation in exercise tolerance and/or episodes precipitated by hyperventilation and/or suppression of episodes by calcium channel blockers. exclusion criteria: (1) age 15 years or older; and (2) suspected vsa with chest pain and evidence of coronary spasm, or vsa diagnosed intraoperatively or at discharge. the following exclusion criteria were applied: (1) failure to meet the diagnostic criteria for vsa; (2) presence of aortic disease, cardiomyopathy, malignant tumor, kounis syndrome, or other diseases that may affect the outcome; (3) insufficient clinical data available; and (4) loss to follow-up.

Keywords: immunomodulatory therapy vasospastic angina cohort study
covid-19 progression in end-stage kidney disease

Conditions: SARS-CoV-2 Infection (Asymptomatic); SARS-CoV-2 Infection (Symptomatic)

Summary: the purpose of this study is to collect genomic and clinical data among a cohort of hemodialysis patients and analyze the association between genetic markers and the development and severity of illness in response to sars-cov-2.

covid-19 is a novel illness caused by the sars-cov-2 virus. it was declared as a global pandemic on march 11, 2020 and since that time there have been outbreaks on every continent except for antarctica. preliminary understanding of the virus suggests that some fraction of the population does not manifest clinical disease in response to infection, others manifest a relatively benign course of illness, and still others develop a fulminant course that eventuates in the need for intensive care, mechanical ventilation, or even death. the genetic and epigenetic basis for differential susceptibility remains unknown. patients receiving hemodialysis provide a good opportunity to understand genetic and epigenetic susceptibility to sars-cov-2. by virtue of their ongoing requirements for care, such patients cannot shelter at home or maintain social distancing, but must instead report to a clinical care setting on a thrice weekly basis. moreover, such patients often travel to and from dialysis using shared ride services, which furthers opportunity for exposure. preliminary estimates suggest that rates of sars-cov-2 positivity are 2 to 5-fold higher among hemodialysis patients than in the general public. furthermore, frequent contact with the health care system among dialysis patients makes tracking clinical course comparatively easy. the purpose of this study is to collect genomic and clinical data among a cohort of hemodialysis patients and analyze the association between genetic markers and the development and severity of illness in response to sars-cov-2.

Eligibility criteria:
inclusion criteria: * is 18 years or older at the time of consent * ability to provide informed consent. * is currently receiving hemodialysis treatment for end-stage kidney disease at a davita dialysis center. * enrollment in prior genomics study (additional criteria for type b only)